ライフサイエンスコーパス: disease duration

1 significantly associated with differences in disease duration.

2 f early active plaques rapidly declined with disease duration.

3 ecline of clinical outcome measures based on disease duration.

4 effect of TREM2 genotype on age at onset and disease duration.

5 s of retinal atrophy, decline in vision, and disease duration.

6 entral macular thickness, visual acuity, and disease duration.

7 nent cerebellar signs, which were related to disease duration.

8 ly in the inner layers of patients with long disease duration.

9 ndent from age, sex, biological markers, and disease duration.

10 cted in Parkinson disease patients with long disease duration.

11 area, number of SC T2 lesions, age, sex, and disease duration.

12 fy biomarker panels that could predict total disease duration.

13 -nitrotyrosine, both of which increased with disease duration.

14 out of STN DBS effects varies with Parkinson disease duration.

15 s in the NAWM of MS patients with increasing disease duration.

16 parkin-mutation carriers (<3%), despite long disease duration.

17 n serum correlated with disease severity and disease duration.

18 f controls as well as in patients with short disease duration.

19 HCs, and showed an association with EDSS and disease duration.

20 s with sustained disease-activity and longer disease duration.

21 0.80, P<.010) were inversely correlated with disease duration.

22 HAQ DI score was seen across the spectrum of disease duration.

23 it did not appear to vary with age, sex, or disease duration.

24 eature of the disease that is independent of disease duration.

25 had died by dividing time to a milestone by disease duration.

26 disease and whose efficiency decreases with disease duration.

27 sociate with serum vitamin D levels, age, or disease duration.

28 of lung disease were similar irrespective of disease duration.

29 on-neurological controls and correlated with disease duration.

30 tiple sclerosis groups that were matched for disease duration.

31 Panuveitis was associated with longer disease duration.

32 her pathologic variables are associated with disease duration.

33 in comparison to controls and increased with disease duration.

34 experience smaller disease burden and longer disease duration.

35 efficiency was significantly correlated with disease duration.

36 Disease severity increased with disease duration.

37 complex profiles were associated with longer disease duration.

38 tion of regional and total brain scores with disease duration.

39 ymptoms and signs, rates of progression, and disease duration.

40 easurements and pulmonary function tests and disease duration.

41 may not apply to populations with different disease durations.

42 pronounced in those with a relatively short disease duration (0-2 years; annualized decline 7.0%).

43 patients with relapsing-remitting MS (median disease duration, 0.8 year) were analyzed by using the s

44 MARDs (median DAS28 1.65 versus 1.78, median disease duration 120 months versus 90 months, and median

45 s disease (11 females, age 57 +/- 9.1 years, disease duration 13.3 +/- 6.3 years) who received bilate

46 ng-remitting multiple sclerosis (>/= 4 years disease duration), 13 subjects with secondary progressiv

47 d 264 MS patients (mean age 46.9+/-10 years, disease duration 14.6+/-10 years; 67.8% relapsing-remitt

48 e at diagnosis, 63.9 [10.3] years; mean [SD] disease duration, 14.6 [7.7] years) were studied.

49 omen; monthly attack frequency: 3.2 +/- 2.5; disease duration: 14 +/- 8.4 years) and 115 matched heal

50 le, 625 female), mean age 49 years with mean disease duration 17 years.

51 ndrome/early multiple sclerosis (</= 3 years disease duration), 18 subjects with relapsing-remitting

52 +/- SD age 46.5 +/- 11.8 years, mean +/- SD disease duration 19.4 +/- 15.9 months).

53 Patients with somatic mutations had a longer disease duration (37 vs 8 months, P < .04), and shorter

54 ve patients with probable AD and matched for disease duration (45 German-Italian bilingual speakers a

55 Inclusion criteria were age 48-65 years, disease duration 5 years or longer, motor fluctuations,

56 62 +/- 7 years; education = 16 +/- 3 years; disease duration = 5.8 +/- 3.9 years) and 27 controls (a

57 patients (13 males and 18 females; mean [SD] disease duration, 5.9 [3.6] years), bright LT resulted i

58 female; mean age at death 64.7 years; median disease duration 6.5 years, range 2.2 to 15.6 years).

59 of 79 patients with newly diagnosed PD (mean disease duration 8 months) and 20 unrelated controls.

60 s disease (mean age 63.8 years +/- 6.8; mean disease duration 9.4 years +/- 2.5) both OFF and ON levo

61 There were no significant differences in disease duration across these age groupings, nor were th

62 and 41% of that with SARA were explained by disease duration, age at onset and the shorter abnormal

63 s, after controlling for variables including disease duration, age, gender, disability and treatment.

64 or any brain region and lesion regardless of disease duration, age, or disability in any RR MS patien

65 sion analysis, choroidal thickness, age, and disease duration (all P < 0.01) all were significant pre

66 A correlation between radial diffusivity and disease duration along the corticospinal tracts (r = 0.8

67 ittle is known about which factors influence disease duration among patients with DLB.

68 mutation except for an indication of longer disease duration and age in patients with highest mutati

69 The Medalist cohort, with a mean +/- SD disease duration and age of 56.2 +/- 5.8 and 67.2 +/- 7.

70 elated to aura and WMHs (P < .01) but not to disease duration and attack frequency.

71 eduction was positively associated with both disease duration and cumulative oral steroid dose.

72 y white matter volume changes are related to disease duration and cumulative oral steroid use, this m

73 ich was mainly attributable to variations in disease duration and differences in the mean/median age

74 ts with type 2 diabetes is dependent on both disease duration and glycaemic control.

75 ortem neuroimaging, directly correlated with disease duration and inversely correlated with brain wei

76 celerated disease onset as well as shortened disease duration and lifespan.

77 form patients and caregivers of the expected disease duration and may help with care planning.

78 disability outcomes, with trends for longer disease duration and older age at first treatment.

79 ns, which showed a negative correlation with disease duration and overlapped with striatal regions sh

80 Disease duration and Parkinson disease functional and st

81 ayer thickness was inversely correlated with disease duration and Parkinson disease severity, and was

82 more likely among obese females with longer disease duration and poor glycemic control.

83 lacking functional T lymphocytes lengthened disease duration and prolonged survival.

84 nd M2 microglia, and resulting in lengthened disease duration and prolonged survival; the stable dise

85 Baseline variables including age, disease duration and relapse rate were compared in univa

86 The two groups were matched for age, disease duration and severity and daily intake of levodo

87 Correlation with disease duration and severity highlights the need for ra

88 tients were matched for age, sex, verbal IQ, disease duration and severity of motor features.

89 = 18, 72.0 +/- 4.7 years) groups matched for disease duration and severity.

90 f having renal disease, after adjustment for disease duration and sex (odds ratio 0.85, 95% confidenc

91 Adjusted for age, sex, disease duration and smoking history, pRBD was associate

92 and degree of SI on DWI that correlates with disease duration and the degree of spongiosis.

93 significant correlation was observed between disease duration and the Expanded Disability Status Scal

94 sability (Expanded Disability Status Score), disease duration and time on treatment.

95 s was examined adjusting for age, sex, race, disease duration and treatment status.

96 severe clinical course, including a shorter disease duration and younger age at death.

97 th diabetes mellitus (especially with longer disease duration) and hyperlipidemia or obesity were ass

98 repeat expansion by analyzing age at onset, disease duration, and age at death in successive generat

99 The generational effect on age at onset, disease duration, and age at death was estimated using a

100 Generational effect on age at onset, disease duration, and age at death.

101 for age, sex, randomized treatment, region, disease duration, and baseline EDSS score.

102 ullinated peptide (anti-CCP) antibody titer, disease duration, and C-reactive protein level on aberra

103 Data concerning demographics, age at onset, disease duration, and clinical and pathological features

104 significantly lower tryptase levels, shorter disease duration, and earlier disease onset.

105 or potential baseline confounders (sex, age, disease duration, and EDSS score), exposure to interfero

106 t Thal amyloid phase predicted age at onset, disease duration, and final Mini-Mental State Examinatio

107 maternal education, seizure disorder, kidney disease duration, and genetically defined ancestry.

108 Randomization was balanced for age, sex, disease duration, and glutamic acid decarboxylase autoan

109 ith pain had an earlier age of onset, longer disease duration, and higher depression and motor severi

110 to evaluate the influence of baseline BCVA, disease duration, and ischemia on BCVA outcomes at month

111 lumes, adjusting for the patients' sex, age, disease duration, and lesion volume.

112 CM and were correlated to corneal sensation, disease duration, and number of recurrences.

113 on) were correlated, adjusting for age, sex, disease duration, and optic neuritis (ON) history.

114 Clinical presentation, age at onset, disease duration, and rate of cognitive decline differed

115 on functional class, 6-minute walk distance, disease duration, and red cell distribution width also p

116 adjustment for age, sex, years of education, disease duration, and site.

117 , older age at the time of diagnosis, longer disease duration, and the absence of anti-Sm or anti-RNP

118 in ABCA7 is associated with age at onset and disease duration, and the minor allele of rs670139 in MS

119 potential confounders (age, sex, ethnicity, disease duration, and treatment with immunosuppressive a

120 his could not be explained by differences in disease duration, and was confirmed by subsequent PET st

121 phy was correlated with clinical disability, disease duration, and, to a lesser extent, conventional

122 lzheimer's disease with distinctly different disease durations, and correlated the data with APOE gen

123 anxiety and depression are related to age or disease duration; and to assess whether the levels of an

124 dex, Expanded Disability Status Scale score, disease duration, annual relapse rate, and treatment sta

125 in which patients exhibit reproducibly short disease durations are associated with mutations that sho

126 er transplant and evaluated the influence of disease duration as a time-dependent covariate on posttr

127 Mean disease duration at first visit and mean duration of fol

128 , 0.37; P=0.004), and infants with a shorter disease duration at screening were more likely than thos

129 analyses of event-free survival according to disease duration at screening.

130 Age at baseline MRI, disease duration, atrophy, codon 129 methionine valine p

131 analysis adjusted by sex, age at onset, and disease duration attributed to GBA carriers a greater ri

132 bjects (n = 12) with approximately 30 years, disease duration before and 6 months after intrahepatic

133 Disease duration (between 22 and 45 months) was signific

134 the visual hallucinations group had similar disease duration but had significantly higher Lewy body

135 Multiple regression analysis revealed disease duration, but not age, gender or skin involvemen

136 were correlated with severity of disease and disease duration by Spearman correlation.

137 version recovery lesion loads, age, sex, and disease duration), cervical cord GM areas had the strong

138 31.4 +/- 9.0; RRMS: 33.0 +/- 8.7 years; mean disease duration: CIS: 7.2 +/- 15 months; RRMS: 8.0 +/-

139 Disease duration, clinical course, age, and gender contr

140 ya disease and estimate its burden regarding disease duration, clinical presentation, and impact on q

141 1, 2011, and Nov 3, 2016, 244 patients (mean disease duration: clinical management group, 0.9 years [

142 independent cohorts (72 patients with short disease duration [cohort 1] and 240 patients with longer

143 tion [cohort 1] and 240 patients with longer disease duration [cohort 2]) treated at a single German

144 neocortical) LBD was associated with shorter disease duration compared with transitional LBD (beta, -

145 Diffuse LBD was associated with shorter disease duration compared with transitional LBD, and thi

146 Total disease duration, defined as the time from symptom onset

147 ds models that included OCT metrics and age, disease duration, disability, presence of previous unila

148 ence of anti-U1 RNP antibodies, but not with disease duration, disease type, or other autoantibodies.

149 adjustment for age, gender, race, ethnicity, disease duration, disease-modifying therapy, and length

150 logistic regression, adjusting for sex, age, disease duration, duration of follow-up, years of educat

151 d slower washout, while patients with longer disease duration experienced faster washout.

152 d to disease duration: patients with shorter disease duration experienced slower washout, while patie

153 cinosis is positively associated with longer disease duration, fingertip ulcers, and NXP-2 autoantibo

154 Mean disease duration for all SOD1 was 4.6+/-6.0 and 1.4+/-0.

155 attack (54 months) was similar to the median disease duration for AQP4-IgG-positive patients with rLE

156 is of clinically isolated syndrome or MS and disease duration from a first symptom of </= 6 years par

157 Shorter disease duration from cognitive symptom onset to death w

158 Median disease duration from symptom onset to death was 7.51 ye

159 tients with Parkinson's disease at different disease durations from time of diagnosis.

160 pathic cardiomyopathy (0.4 [0.2-1]), cardiac disease duration greater than 2 years pre-extracorporeal

161 patients with MS of long-standing duration (disease duration >/= 10 years) and in 60 healthy control

162 one percent of patients with "late" disease (disease duration >/= 18 months) had a decline in MRSS, a

163 igible patients (ie, those aged 18-75 years, disease duration >/=3 years, Toronto Western Spasmodic T

164 nclusion criteria were age <22 years and DCM disease duration >2 months.

165 ration <5 years) and 12 with advanced RR MS (disease duration >5 years)-and 15 control subjects.

166 Patients with a shorter disease duration had higher frequencies of insulin-react

167 ly those with a short diagnostic latency and disease duration, had higher plasma NfH levels at an ear

168 hey did differ significantly with respect to disease duration; hemoglobin level; frequency of thrombo

169 expression in astrocytes on onset as well as disease duration highlights the importance of this cell

170 The extent of reduction correlated with disease duration in all subjects with epilepsy.

171 clinical parameters such as focus score and disease duration in human patients.

172 Since OSA disease duration in our subjects is unknown, these findi

173 To identify pathologic correlates of disease duration in participants with Lewy body disease

174 never) and surgery in IBD, and incorporated disease duration in the analysis.

175 In MS, disease duration inversely correlated with right cerebel

176 Surprisingly, disease duration is independent of the mutation's length

177 ugh disease onset and mortality are delayed, disease duration is not affected.

178 Models were adjusted for age, education, disease duration, language, and levodopa equivalent dail

179 six early stage multiple sclerosis subjects (disease duration </=5 years) and 24 age-matched healthy

180 ee percent of patients with "early" disease (disease duration <18 months) had a decline in MRSS, and

181 of patients with RR MS-14 with early RR MS (disease duration <5 years) and 12 with advanced RR MS (d

182 yes or no), weight (<70 kg or >/=70 kg), and disease duration (</=2 years or >2 years) after 8 weeks

183 the improvement rate of patients with short disease durations (<1 year at the first visit) was signi

184 Disease duration, lymphocyte count, and azathioprine use

185 ment for levodopa equivalent dose, sex, age, disease duration, MDS-UPDRS III score at the first asses

186 R47H carriers demonstrated a shortened disease duration (mean [SD], 6.7 [2.8] vs 11.1 [6.6] yea

187 medications at baseline had longer diabetes disease duration (mean, 17.4 and 20.9 years, respectivel

188 ed as semantic dementia, and they had longer disease duration (mean: 15.3 years) compared with the ot

189 ith vs those without calcinosis had a longer disease duration (median, 6.9 years; range, 2.4-18.1; vs

190 .0 years [IQR, 26.3-38.3 years]), with short disease durations (median, 1.0 months [IQR, 1.0-2.0 mont

191 0 years]) consisting of patients with longer disease durations (median, 36.0 months [IQR, 21.0-60.0 m

192 Data regarding disease duration, medications, complications, recent blo

193 wed no significant differences in age, motor disease duration, MoCA, Unified Parkinson Disease Rating

194 5 +/- 7.4 years old; 6.0 +/- 4.2 years motor disease duration; modified Hoehn and Yahr mean stage 2.4

195 e, younger, younger at PD onset, have longer disease duration, more severe non-motor symptoms (includ

196 Neither disease duration nor cumulative oral or intravenous ster

197 , MRI-T1 brain volume, MRI-T2 lesion volume, disease duration, number of previous relapses within 2 y

198 sociated with the primary outcome were short disease duration (odds ratio [OR] 0.64, 95% CI 0.41-0.99

199 ubjects and 30 PD patients at early stage of disease (duration of disease </= 5 y) with mild and unil

200 Somatic mutations in AA patients with a disease duration of >6 months were associated with a 40%

201 observed in tissues from younger donors with disease duration of <10 years.

202 African American RA patients with a disease duration of <2 years (n = 141) were included in

203 et of 15.3 years (range, 3-28 years), a mean disease duration of 12.1 years, and a mean age at baseli

204 was 24 years (range 17-71 years) with median disease duration of 19 years (range 7-67 years).

205 Additional eligibility criteria included disease duration of 2-10 years and objective evidence of

206 and 71 Hispanic SSc patients with an average disease duration of 2.6 years at enrollment.

207 had varying degrees of symptoms, with a mean disease duration of 22 days.

208 e ability to walk independently for a median disease duration of 22 years.

209 ability to walk independently after a median disease duration of 23 years and became wheelchair depen

210 age of 34.4 (range, 28-39) years and a mean disease duration of 28.8 years.

211 At baseline, patients had median disease duration of 3.2 years, median ELF score of 9.8,

212 stribution was decreased by 33% after median disease duration of 4.7 years (0.5-12.4 years).

213 an age, 76.7 years; 93.5% men) with a median disease duration of 55.6 months and mild to moderate hea

214 After median disease duration of 75 months, 18% had developed permane

215 of 51 years (range 34-69 years) and a median disease duration of 8.0 years (range 2-18 years).

216 The mean disease duration of all patients was 15.0 +/- 13.4 mo at

217 ernational panel criteria for diagnosis with disease duration of less than 15 years were eligible.

218 ized nonthymomatous myasthenia gravis with a disease duration of less than 5 years were included if t

219 vere underweight, severe acute malnutrition, disease duration of more than 21 days, and referral from

220 nd 28.5% of patients were in the groups with disease durations of 0-2 years, 2-4 years, and >4 years,

221 ultiple sclerosis-2 group (n = 300) had mean disease durations of 20 +/- standard deviation 10.9 and

222 and between Parkinson disease patients with disease durations of less than or at least 10 years.

223 frequency and spectra of HPRT mutations with disease, duration of illness, duration of treatment, and

224 utative trigger factors, coexisting systemic diseases, duration of symptoms and diagnoses given befor

225 test) higher than that of patients with long disease durations (one year or more).

226 Parents whose child had longer disease duration or a severe reaction and parents who we

227 No generational effect was observed for disease duration or age at death.

228 led to show a benefit in patients with short disease duration or an increased level of C-reactive pro

229 occurs in individuals with MS regardless of disease duration or chronological age of the patient.

230 , the mean amplitude was not correlated with disease duration or other clinimetric scores.

231 f glucocorticoids (weak evidence) but not to disease duration or severity/activity, gender, age, or A

232 pathogenic coding variants did not influence disease duration or site of onset.

233 g the SP phase increased proportionally with disease duration (OR=1.07 for each additional year; p<0.

234 etween GABA responses, demographic features, disease duration, or disease severity in the whole popul

235 ed by age at onset (P < 0.0001) and by total disease duration (P < 0.0001).

236 ereas only the cervical cord correlated with disease duration (p < 0.05).

237 ders had lower endoscopy scores during their disease duration (P = .013).

238 resent in younger individuals with a shorter disease duration (P = .02).

239 d imaging (P = .003, corrected) but not with disease duration (P = .089, corrected).

240 nzymatic activity was associated with longer disease duration (P = 0.002) in adjusted models, suggest

241 n severity was significantly associated with disease duration (P = 0.02), and COMT rs6267 T allele (P

242 e HCVA (p = 0.02) and worse LCVA per year of disease duration (p = 0.039).

243 d for increased atrophy was seen with longer disease duration (P = 0.13).

244 Physical scores increased with age and disease duration (p<0.001, p<0.001), but there was a wea

245 Despite similar age and disease duration, patients with the diffuse/malignant ph

246 , and this variation was strongly related to disease duration: patients with shorter disease duration

247 cts were matched first for age at death then disease duration (PD only) for comparison.

248 founding factors of sexual dysfunction: age; disease duration; physical disability; depression; bladd

249 Severity of dystonia preoperatively and disease duration predicted improvement in severity of dy

250 emographic and disease characteristics (age, disease duration, previous treatment with disease-modify

251 regression adjusted for age, calendar year, disease duration, propensity scores, and use of other IB

252 0.6) at follow-up (P = .001) correlated with disease duration (r = 0.47, P = .003 at baseline and r =

253 e choriocapillaris and the Sattler layer and disease duration (R2 = 0.98 and R2 = 0.99, respectively;

254 e obtained from 45 cadaveric T1D donors with disease durations ranging from 1 wk to >50 yr, 14 nondia

255 None of these variables, including disease duration, reliably identifies groups of subjects

256 ), where MTR also showed an association with disease duration (rho=-0.86, p<0.001).

257 found between the (11)C-donepezil signal and disease duration, severity of constipation, gastric empt

258 After adjusting for disease duration, severity of corticospinal tract degene

259 remaining insulin-containing islets and long disease duration show elevated levels of CD8 T cells in

260 multivariate model adjusted for age, gender, disease duration, smoking status, vitamin D levels, body

261 r performance than did noncarriers with long disease duration, suggesting slower disease progression.

262 significantly differ in mean age (t=1.09) or disease duration (t=0.44) compared to patients with seve

263 Correlations with disease duration, T2 lesion volume, brain volume, and re

264 dementia with Lewy bodies (DLB) have shorter disease duration than patients with Alzheimer disease de

265 After conditioning on autoantibody and disease duration, time-averaged DAS28 showed significant

266 PD-ICB were matched for age, gender and disease duration to 42 patients with PD without ICB over

267 ontrols only in patients with ALS with short disease duration to baseline sampling.

268 ng were more likely than those with a longer disease duration to benefit from nusinersen.

269 ual hallucinations had significantly greater disease duration, treatment duration, motor severity and

270 The objective of this study was to document disease duration, treatment history, and disease activit

271 anded Disability Status Scale (EDSS) scores, disease duration, treatments, prior optic neuritis episo

272 Disease duration, Unified Parkinson's Disease Rating Sca

273 ificantly exponential correlations to stage; disease duration; Unified Parkinson Disease Rating Scale

274 Multivariable models for total disease duration using biomarkers from plasma, CSF, and

275 years (SD 9.3), 63.5% were men and the mean disease duration was 1.3 years (SD 0.9).

276 Median age was 60 years (IQR 57-65), disease duration was 11 years (6-25), and DAS28 score wa

277 The median disease duration was 17 years.

278 Mean disease duration was 9.8 years (range: 1.2-32.7 years).

279 ) age was 39.5 (11.2) years and preoperative disease duration was 97.9 (85.8) months; 83 patients (91

280 s. 270.05+/-24.6 mum; P = 0.04), and greater disease duration was associated with decreases in retina

281 Disease duration was mildly negatively predictive of cha

282 een onset of motor and dementia symptoms and disease duration was shorter (p<0.0001 for all compariso

283 Disease duration was significantly shorter in cases with

284 With longer disease duration, we found an additional, progressive ac

285 At baseline, the mean age and the mean disease duration were 52.4 years and 14.8 months, respec

286 Mean age and disease duration were 53 and 19.4 years, respectively.

287 Mean age of onset and disease duration were 70.6 (SD+/- 6.42) and 10.5 (SD+/-

288 whether the number of clinical relapses and disease duration were correlated with all TBSS parameter

289 nd interactions between disease severity and disease duration were explored.

290 On multivariate analysis, HGD, DALM, and disease duration were independent risk factors for posto

291 ilability at rest positively correlated with disease duration were lateral and non-overlapping with s

292 Fingertip ulcers and disease duration were strongly associated with calcinosi

293 acuity, central macular thickness (CMT), and disease duration were the main outcomes.

294 aphs, obtained at baseline and at 3 years of disease duration, were scored using the modified Sharp/v

295 aring white matter (NAWM) corresponding with disease duration, when corrected for age.

296 ctions were greater in patients with shorter disease duration, which suggests a potential benefit of

297 nresponders spent 54% and 97% of their total disease duration with active EoE (P < .001) and 23% and

298 gan donors with type 1 diabetes with a short disease duration with high-risk HLA genes using a direct

299 g-remitting (RR) MS patients of 0.3-12 years disease duration with multivoxel (four sections of 80 1-

300 unization delayed disease onset and extended disease duration, with survival times increased by an av